Several reasons have been discussed for the failure of the large trials with subcutaneous administration of IGF-1, in particular, problems with bioavailability or lack of knowledge on how IGF-1 interacts with specific cellular pathways that are dysfunctional in ALS. This evidence concerns the gene IGF1 and amyotrophic lateral sclerosis.